CBD Products

Zyn002 cbd gel

3 Dec 2018 NEW ORLEANS — Treatment with ZYN002, an investigational transdermal cannabidiol (CBD) gel, was well-tolerated and consistently effective  7 May 2019 The Food and Drug Administration (FDA) has granted Fast Track designation to Zygel (ZYN002; Zynerba), a cannabidiol gel for the treatment of  26 Aug 2019 ZYN002 is a synthetic CBD gel delivered transdermally. ZYN002 is indicated for use in disorders such as fragile X syndrome, developmental  21 Nov 2019 Zynerba: CBD and Transdermal Delivery portfolio covering the company's transdermal CBD product candidate, Zygel (ZYN002 CBD gel). 24 Oct 2019 Zynerba is developing Zygel (ZYN002), a transdermal CBD gel, which is presently in clinical trial. In April 2018, Zynerba initiated the Phase 2 of 

2 Aug 2019 The aim of the current study was to evaluate the safety, tolerability, and initial efficacy of ZYN002, a transdermal CBD gel, in a pediatric 

25 Nov 2019 Primary Objective: This study will evaluate the efficacy and safety of ZYN002, a clear cannabidiol (CBD) gel that can be applied to the skin  The Drug Product ZYN002 is a pharmaceutically manufactured CBD. It is being developed as a clear gel that can be applied to the skin (called transdermal  11 Jun 2019 ZYNE has been working hard to protect its cannabidiol product candidate, Zygel, also known as ZYN002 transdermal CBD gel. In recent  20 Sep 2017 A week later, Zynerba had similar bad news in their Phase 2 study with the same product, ZYN002-CBD Gel for an osteoarthritis indication. 7 Aug 2017 Two doses of Zynerba's ZYN002 gel were tested against a placebo in the to file a U.S. marketing application for its CBD-based epilepsy drug,  31 Jan 2018 Zynerba Pharmaceuticals Inc. NASDAQ ZYNE is developing ZYN002 a CBD Gel. The pitch for the drug's uniqueness is that its patented  3 Dec 2018 A twice-daily, 390-mg dose of the gel, dubbed ZYN002 (Zynerba) for now, was consistently effective in the 24-month STAR 2 extension trial, 

Zynerba Pharmaceuticals’ investigative therapy ZYN002 — a pharmaceutically produced cannabidiol (CBD) gel — was seen to significantly improve behavioral symptoms in children and adolescents with fragile X syndrome (FXS), according to new Phase 2 clinical data.

Zynerba Stock Pops On CBD Gel Patent - Green Market Report Zynerba Pharmaceuticals, Inc. (ZYNE) stock popped over 8% in early trading to lately trade at $5.45 after the company announced that it had received a patent covering the company’s CBD gel. The company said in a statement, “The U.S. Patent and Trademark Office has issued US Patent No. 10,213,390, titled “Treatment of Fragile X Syndrome … A phase 1/2, open-label assessment of the safety, tolerability, The aims of the present study were to test the safety, tolerability, and efficacy of ZYN002, a transdermal, pharmaceutically manufactured, CBD gel, in a pediatric sample with FXS. We hypothesized that 12 weeks of ZYN002 treatment would be well-tolerated and lead to significant reductions in the most common and difficult behaviors associated with FXS. Zynerba Pharmaceuticals Announces Initiation of STAR 2 Open-Label 02.11.2016 · Zynerba Pharmaceuticals Announces Initiation of STAR 2 Open-Label Extension Clinical Trial for ZYN002 CBD Gel in Adult Refractory Epilepsy Patients

ZYN002 CBD gel is the first and only patent-protected, synthetic CBD that is formulated as a permeation-enhanced gel for transdermal delivery, and was awarded orphan drug designation by the U.S. Food and Drug Administration for the treatment for FXS.

20 Sep 2017 A week later, Zynerba had similar bad news in their Phase 2 study with the same product, ZYN002-CBD Gel for an osteoarthritis indication. 7 Aug 2017 Two doses of Zynerba's ZYN002 gel were tested against a placebo in the to file a U.S. marketing application for its CBD-based epilepsy drug,  31 Jan 2018 Zynerba Pharmaceuticals Inc. NASDAQ ZYNE is developing ZYN002 a CBD Gel. The pitch for the drug's uniqueness is that its patented  3 Dec 2018 A twice-daily, 390-mg dose of the gel, dubbed ZYN002 (Zynerba) for now, was consistently effective in the 24-month STAR 2 extension trial,